6 -Ser 7 . This unusual structure serves as a platform for the binding of factors required for expression of pol II-transcribed genes, including the small nuclear RNA (snRNA) gene-specific Integrator complex. The pol II CTD specifically mediates recruitment of Integrator to the promoter of snRNA genes to activate transcription and direct 3 end processing of the transcripts. Phosphorylation of the CTD and a serine in position 7 are necessary for Integrator recruitment. Here, we have further investigated the requirement of the serines in the CTD heptapeptide and their phosphorylation for Integrator binding. We show that both Ser 2 and Ser 7 of the CTD are required and that phosphorylation of these residues is necessary and sufficient for efficient binding. Using synthetic phosphopeptides, we have determined the pattern of the minimal Ser 2 /Ser 7 double phosphorylation mark required for Integrator to interact with the CTD. This novel double phosphorylation mark is a new addition to the functional repertoire of the CTD code and may be a specific signal for snRNA gene expression.
The CTD 5 of the largest subunit of pol II is an evolutionary conserved structure, specific to eukaryotic organisms, which plays a fundamental role in transcription and RNA processing (1) . It comprises multiple tandemly repeated heptapeptides with the consensus sequence Tyr -Pro 6 -Ser 7 , with 52 repeats in the mammalian protein (2) . The CTD serves as a scaffold for the interaction of a wide range of nuclear factors involved in various processes linked to transcription. The ability of the CTD to interact specifically with appropriate proteins during the transcription cycle in vivo is determined largely by the phosphorylation status of the three serine residues within the consensus heptapeptide (Ser 2 /Ser 5 /Ser 7 ) (3). Different patterns of CTD serine phosphorylation correlate with the position of pol II along transcribed protein-coding genes and allow the recruitment of the appropriate factors at different stages of the transcription cycle. Differential modification thus enables a wide range of signaling combinations to be read as a code (3) (4) (5) . Phosphorylation of Ser 2 and phosphorylation of Ser 5 are the best studied CTD modifications. Ser 5 phosphorylation is directed by the CDK7 kinase as part of the TFIIH complex. Ser 5 phosphorylation occurs early in the transcription cycle, is highest near the promoter, and activates capping of mRNAs. Ser 2 phosphorylation, directed by the CDK9 kinase subunit of the positive transcription elongation factor b (P-TEFb) complex, occurs later in the transcription cycle and is generally highest toward the 3Ј end of the genes. This modification plays roles in splicing and 3Ј end processing of transcripts. There is some evidence that CTD heptapeptides can bear both Ser 2 and Ser 5 marks as factors implicated in transcription such as Set2 preferentially recognize a combination of both in vitro (3, 6) . Some Ser 2 phosphorylation must therefore occur before the removal of the phosphate on Ser 5 . Recently, it has been shown that Ser 7 of the heptapeptide repeat is also phosphorylated during transcription (7) (8) (9) (10) , further expanding the number of possible phosphorylation combinations on the CTD. The CDK7 component of the general transcription factor TFIIH has been implicated in Ser 7 phosphorylation both in vivo and in vitro (7, 10, 11) . The CDK9 component of P-TEFb has also been shown to have Ser 7 kinase activity (10). Ser 7 phosphorylation has been found on both protein-coding genes and the pol II-transcribed snRNA genes (7) (8) (9) (10) (11) . Human snRNA genes transcribed by pol II are structurally different from protein-coding genes (12, 13) . snRNAs are neither spliced nor polyadenylated, and instead of a polyadenylation signal, the genes contain a conserved 3Ј box RNA-processing element downstream of the snRNA-encoding region (14) . However, these two different gene types share a requirement for the pol II CTD for efficient transcription and RNA processing (15) (16) (17) (18) (19) . The demonstration that the snRNA gene-specific Integrator complex, which is required for 3Ј box recognition, binds to the pol II CTD (20) provided a molecular link between transcription and 3Ј processing of snRNA gene transcripts. More recently, we have shown that the serine in position 7 of the CTD heptapeptide plays a pivotal role in expression of snRNA genes (9 (20) . In addition, we demonstrate that Ser 7 kinase activity in HeLa cell nuclear extracts is largely attributable to DNA-PK and that recombinant DNA-PK specifically phosphorylates Ser 7 of GST-CTD fusion proteins with 25 heptapeptide repeats in vitro.
EXPERIMENTAL PROCEDURES
Superose 6 Fractionation-200 l of HeLa nuclear extract in 20 mM Hepes, pH 7.9, 100 mM KCl, 20% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 0.2 mM EDTA (Buffer D) (21) was loaded onto a Superose 6 column, and 0.5-ml fractions were collected. Molecular weight protein standards were run through the same column under the same conditions.
GST-CTD Phosphorylation-0.1 g of GST-CTD (25 repeats) was incubated with 20 l of fraction or 0.2-1 l of HeLa nuclear extract in a 40-l final volume of 20 mM Hepes-NaOH, pH 7.9, 8 mM MgCl 2 , 20 mM creatine phosphate, 5 mM ␤-glycerol phosphate, 50 mM KCl, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 1 mM ATP, 0.4 l of Sigma phosphatase inhibitor mixture 1 (kinase buffer) for 15 h at 30°C. For recombinant DNA-PK (Promega) studies, 50 units were incubated with 0.1 mg of GST-CTD (25 repeats) according to the manufacturer's instructions. For inhibitor studies, wortmannin (Invitrogen) was preincubated with the reaction mix for 10 min at 30°C prior to the addition of ATP and GST-CTD substrate. Activated calf thymus DNA (Sigma) was added to the reaction mix as indicated. Reactions were stopped by boiling in SDS buffer, and phosphorylation was analyzed by Western blot with phospho-CTD-specific antibodies.
GST-CTD Pulldown-GST-CTD pulldowns were performed as described previously (9) .
CTD Peptide Binding Assay-CTD peptides were synthesized (Cambridge Peptides) with one, two, or four repeats of YSPTSPS or YAPTSPA and amino-terminal biotinylation. Ser 2 /Ser 7 phosphorylated peptides were also made. For the Integrator binding assay, 20 l of streptavidin-coated Sepharose beads was resuspended in 0.1 M KCl HEGN, mixed with 10 g of biotinylated peptides, and incubated at 4°C for 1 h. After washing four times with 0.1 M KCl HEGN, 1 ml of the P11 0.5 M KCl fraction (precleared with streptavidin beads for 1 h) was added, and the mixture was incubated at 4°C for 3 h. After washing the beads five times with 1 ml of 0.3 M KCl HEGN, protein-bound beads were boiled and loaded on SDS-PAGE gels directly.
Western Blot Analysis-Western blotting was carried out as described (22) using antibodies against Int11 (23), CTDSer(P) 2 , Ser(P) 5 , and Ser(P) 7 (8), CDK9 (Santa Cruz Biotechnology, SC484), cyclin T1 (Santa Cruz Biotechnology, SC8128), Int7 (Bethyl Laboratories, DKFZP434B168), CDK7 (Santa Cruz Biotechnology, SC529), and DNA-PKcs (Santa Cruz Biotechnology, SC1552).
RESULTS

Both Ser 2 and Ser 7 of the CTD Are Required for Binding of the Integrator Complex-The
Integrator complex comprises 12 subunits totaling ϳ2 MDa and has been shown to interact with the CTD of pol II in vitro (9, 20) . It is associated with U1 and U2 snRNA genes, as shown by chromatin immunoprecipitation, and is required for recognition of the snRNA gene-specific 3Ј box (9, 20) , which directs 3Ј end formation of pre-snRNA (13, 14) . The Integrator complex may also play a role in activating transcription of snRNA genes, at a step downstream of pol II recruitment (9) . The role of most of the 12 Integrator subunits is unclear, but two subunits, Int9 and Int11, display sequence homology to the CPSF-100 and CPSF-73 subunits of the cleavage and polyadenylation specificity factor, respectively (20, 23) . Int11 is therefore thought to carry the endonuclease activity responsible for the first cleavage during the formation of the 3Ј end of pre-snRNAs (20) . We have previously shown that in vitro binding of Int11 to the CTD requires phosphorylation of the CTD (9) . Mutation of Ser 7 in the heptapeptide consensus sequence affects the interaction between the CTD and Integrator in vitro and prevents its recruitment on snRNA genes in vivo, suggesting that Ser 7 phosphorylation participates in Integrator recruitment to snRNA genes (9) . However, the CTD is the site of multiple phosphorylations, with all three serines phosphorylated in vitro (9) . To investigate the role of Ser 2 , Ser 5 , and Ser 7 phosphorylation, we performed glutathione S-transferase (GST) pulldown analysis with GST-CTDs carrying 25 consensus (wild type), S2A, S5A, or S7A heptapeptide repeats (Fig. 1) . For detection of the catalytic subunit, Int11 was used as a diagnostic for Integrator binding to the CTD. As expected, Integrator interacts strongly with the consensus repeats after phosphorylation of the CTD. Mutation of Ser 2 and Ser 7 to alanine has a drastic effect on Integrator binding, demonstrating that these residues are critical for this interaction. In contrast, mutation of Ser 5 does not reduce the binding of Integrator but rather enhances it, excluding any positive role of Ser 5 7 Kinase Activities Can Be Separated in VitroThe requirement for CTD phosphorylation and serines at positions 2 and 7 can be explained by three distinct scenarios. Binding of the Integrator complex to the CTD requires: 1) a phospho-serine in position 2 and a serine in position 7; 2) a serine in position 2 and a phospho-serine in position 7; or 3) phospho-serines in positions 2 and 7. To discriminate between Novel CTD Phosphorylation Mark JULY 2, 2010 • VOLUME 285 • NUMBER 27
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these possibilities, we separated Ser 2 and Ser 7 kinase activities in vitro. HeLa nuclear extract was fractionated on a Superose 6 size exclusion column, and the ability of each fraction to phosphorylate GST-CTD containing 25 consensus repeats in vitro was tested by Western blot with antibodies specific to phosphoSer 2 , phospho-Ser 5 , and phospho-Ser 7 (8) (Fig. 2A) . The fractions were also tested for the presence of the CTD kinases CDK7 and CDK9, the cyclin T1 partner of CDK9, and the Int7 subunit of the Integrator complex. Interestingly, Ser 7 kinase activity, which is present in fractions 16 -36 and peaks in fractions 16 and 26 -28, can be separated from Ser 2 and Ser 5 kinase activities, which are present in fractions 28 -36, with only a small amount of Ser 2 kinase activity in fraction 16. Thus, a high level of Ser 7 kinase activity fractionates together with Cdk9, cyclin T1, and the large Integrator complex with an apparent molecular mass of Ͼ2 MDa (20) . A second peak of Ser 7 kinase activity fractionates with an apparent molecular mass of ϳ500 -700 kDa, whereas Ser 2 and Ser 5 kinases fractionate between 50 and 500 kDa. As expected, the pattern of Ser 5 phosphorylation closely follows the two isoforms of Cdk7. In contrast, the two major isoforms of the Ser 2 kinase Cdk9 do not closely correlate with the Ser 2 phosphorylation pattern, although the antibody detects some bands between the two isoforms in the fractions active for Ser 2 phosphorylation. Similarly, Ser 7 phosphorylation does not correlate closely with the presence of either CDK7 or CDK9, as might be expected (7, 10, 11) , although some Ser 7 kinase activity is present in the fractions where CDK7 and CDK9 are detected. However, Ser 7 kinase activity in fractions 16 -30 correlates closely with the presence of the 460-kDa catalytic subunit of the DNA-activated kinase DNA-PK, which has CTD kinase activity (24) and has been shown to phosphorylate CTD peptides on Ser 7 (25) . In addition, the DNA-PK inhibitor, wortmannin (26) , effectively and selectively inhibits Ser 7 phosphorylation by nuclear extracts (Fig. 2B) A, fractions from HeLa nuclear extract fractionation on a Superose 6 column were tested for the ability to phosphorylate the CTD. The results of Western blot analysis using the phospho-specific antibodies (8) to the modifications noted at the right are shown in the top three panels. The results of Western blot analysis of the fractions using antibodies to the proteins noted at the right are shown in the bottom five panels. The fraction numbers and size of molecular weight (MW) standards are shown at the top. Ip indicates input. Ser2 P , Ser(P) 2 ; Ser5 P , Ser(P) 5 ; Ser7 P , Ser(P) 7 . B, Western blot analysis of GST-CTD phosphorylation by nuclear extract supplemented with wortmannin (left panel) or DNA (right panel) using the phospho-specific antibodies noted at the left. C, Western blot analysis of GST-CTD phosphorylation by recombinant DNA-PK supplemented with wortmannin (left panel) or DNA (as a time course) (right panel) using the phospho-specific antibodies noted at the left.
by adding double-stranded DNA, as expected for DNA-PK (27) (Fig. 2B) . In addition, recombinant DNA-PK phosphorylates the GST-CTD fusion protein on Ser 7 , and this activity is inhibited by wortmannin and activated by double-stranded DNA (Fig. 2C) . DNA-PK was also previously found to phosphorylate CTD peptides on Ser 2 (25) . Recombinant DNA-PK also has some Ser 2 kinase activity toward the GST-CTD substrate. However, this is neither inhibited by wortmannin nor activated by double-stranded DNA and is significantly lower than Ser 7 kinase activity (Fig. 2C) , and 36 were independently used to phosphorylate a GST-CTD containing 48 consensus repeats. As expected, the GST-CTD is differentially modified depending on the fraction used for in vitro phosphorylation (Fig. 3 ). CTDs were then tested for their ability to interact with Integrator using the binding assay described in Fig. 1 A Specific Mark on the CTD Directs the Binding of Integrator-As a final step, we designed a set of N-terminally biotinylated peptides to further characterize the Integrator binding motif on the CTD (Fig. 4) . First, we determined the minimal number of CTD repeats required for efficient Int11 binding. CTD peptides consisting of 2-4 heptapeptide repeats were tested for their ability to interact with Integrator before or after in vitro phosphorylation (Fig. 4A) . As expected, nonphosphorylated peptides were unable to bind Integrator. In contrast, Int11 interacts with in vitro phosphorylated CTD peptides comprising two and four repeats. This result demonstrates that two repeats are sufficient for Integrator binding and is in accordance with the previous demonstration in yeast that the basic unit of the CTD comprises two repeats (28) . Importantly, an in vitro phosphorylated CTD peptide containing only one repeat failed to FIGURE 3. Phosphorylation of both Ser 2 and Ser 7 is required for Integrator binding. Fractions (Frac.) containing Ser 2 kinase activity, Ser 7 kinase activity, or both were used to phosphorylate GST-CTD and tested for their ability to bind the Integrator complex, as indicated in the scheme on the left. The results of Western blot analysis using anti-Int11 antibodies (23) (top), Coomassie Blue staining of the input GST-CTD (middle), and Western blot analysis using antibodies to phospho-Ser 2 (Ser2 P ) and phospho-Ser 7 (Ser7 P ) (bottom) are shown on the right. NE ϭ nuclear extract. 
